Seminal plasma accelerates semen-derived enhancer of viral infection (SEVI) fibril formation by the prostatic acid phosphatase (PAP 248-286) peptide

Joanna S. Olsen, John T.M. DiMaio, Todd M. Doran, Caitlin Brown, Bradley L. Nilsson, Stephen Dewhurst

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Amyloid fibrils contained in semen, known as SEVI, or semen-derived enhancer of viral infection, have been shown to increase the infectivity of HIV dramatically. However, previous work with these fibrils has suggested that extensive time and nonphysiologic levels of agitation are necessary to induce amyloid formation from the precursor peptide (a proteolytic cleavage product of prostatic acid phosphatase, PAP 248-286). Here, we show that fibril formation by PAP 248-286 is accelerated dramatically in the presence of seminal plasma (SP) and that agitation is not required for fibrillization in this setting. Analysis of the effects of specific SP components on fibril formation by PAP 248-286 revealed that this effect is primarily due to the anionic buffer components of SP (notably inorganic phosphate and sodium bicarbonate). Divalent cations present in SP had little effect on the kinetics of fibril formation, but physiologic levels of Zn 2+ strongly protected SEVI fibrils from degradation by seminal proteases. Taken together, these data suggest that in the in vivo environment, PAP 248-286 is likely to form fibrils efficiently, thus providing an explanation for the presence of SEVI in human semen.

Original languageEnglish (US)
Pages (from-to)11842-11849
Number of pages8
JournalJournal of Biological Chemistry
Volume287
Issue number15
DOIs
StatePublished - Apr 6 2012

Fingerprint Dive into the research topics of 'Seminal plasma accelerates semen-derived enhancer of viral infection (SEVI) fibril formation by the prostatic acid phosphatase (PAP <sub>248-286</sub>) peptide'. Together they form a unique fingerprint.

Cite this